Biogen Inc. BIIB measures an EPS growth for 2017 at a rate of 3.32% that consequently shows an EPS growth of 31.30% for the past five years, and an EPS growth of 9.01% for the following five years. (NASDAQ:BIIB) has a target of $346.785 on a consensus basis. Biogen has a 12 month low of $223.02 and a 12 month high of $338.51. Shares rose to $330.11, a roughly $6 billion increase in market capitalization for the Cambridge, MA-based biotech. The stock kept floating in a price range of $18.10 – 20.59. The company had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.79 billion. During the same quarter in the previous year, the company posted $4.22 EPS. Scangos will leave after Biogen finds a successor but his loss added to investors getting more and more exhausted with the slowdown in the company’s multiple sclerosis franchises could prove a key factor in Biogen is ultimately accepting a takeover to escape from a risky position.
Advertisement
It was unclear whether other drug giants are contemplating acquiring the company, which is in the process of searching for a new CEO. The stock is now holding above its 50-day SMA of $26.88 and above its 200-day SMA of $257.1. In 2015, the shares of the company dipped to $500 due to the slow and stagnant growth of its blockbuster molecule Tecfidera, due to fierce competition by Roche competition. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Dev.in the company, Koppel Adam, on Monday June 06, 2016 collected $160,950 from the sale of 555 shares at a per-share price of $280. The shares were sold at an average price of $289.74, for a total value of $1,116,947.70.
A number of other equities analysts also recently weighed in on BIIB.
07/22/2016 – Biogen Idec Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. Biogen Idec Inc. (NASDAQ:BIIB) is next scheduled to report quarterly earnings on 2016-10-19. That hasn’t stopped some sell-side analysts from fantasizing about acquisition prices of $400 or more in a bevy of research notes. Standpoint Research lowered shares of Biogen from a “buy” rating to a “hold” rating in a research note on Tuesday. If such a deal were to go through, then it would create a massive pharmaceutical company, capable of driving market prices and the prices of a lot of medications. Biogen presently has an average rating of “Buy” and an average price target of $341.84. Analysts began matchmaking for the Dublin pharma as soon as its megamerger with Pfizer fell through, and some put Biogen near the top of the company’s potential target list.
Advertisement
Founded in 1978, Biogen is one of the world’s oldest biotechnology companies focusing on treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders and its leading therapies include multiple sclerosis and hemophilia.
